Brief: Verastem Oncology Doses First Patient In Target-D 202 Phase 2 Registration-Directed Trial Of Versus-7375 For Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer
22/07/2026 22:57
BRIEF-Verastem Oncology Doses First Patient In Target-D 202 Phase 2 Registration-Directed Trial Of Versus-7375 For Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer July 22 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 202 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VERSUS-7375 FOR KRAS G12D-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Source text: ID:nBw8Gh5BSa
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))